A recently published study clearly demonstrated that Modufolin® administration resulted in significantly higher methylenetetrahydrofolate levels than Isovorin® administration.

Isofol Medical AB announces publication of a study comparing the concentration of folate metabolites in tumor, mucosa, and plasma of patients with colon cancer after administration of Modufolin® or Isovorin® (levo-leucovorin). The results support Isofol’s belief that Modufolin® has the potential to increase the efficacy of 5-fluorouracil-based chemotherapy for many patients. Results clearly demonstrated that Modufolin® administration resulted in significantly higher methylenetetrahydrofolate levels than Isovorin® administration. Isofol will continue to evaluate the potential of Modufolin® as a substitute to Isovorin® in the treatment of patients with colon cancer.

The publication entitled “A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study” is published in Cancer Chemotherapy and Pharmacology and is available online via PubMed at: http://www.ncbi.nlm.nih.gov/pubmed/25342290.

About Modufolin®

Modufolin®(chemical name [6R] 5,10 methylenetetrahydrofolate), is a novel folate-­‐based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used folate based drugs today including Leucovorin and Levoleucovorin and therefore does not require metabolic activation. This makes Modufolin® suitable for all patients irrespective of their capacity to activate folates and it is currently evaluated in clinical phase II studies.

For more information, please contact:

Anders Rabbe, CEO, Isofol Medical AB

E‐mail: anders.rabbe@isofolmedical.com; 

Phone: +46 (0)707 646 500 

Modufolin® is a registered Trademark of Merck KGaA, Darmstadt, Germany.